17β-mercapto-androst-5-en-3β-ol | 21002-48-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17β-mercapto-androst-5-en-3β-ol
• 英文别名: (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-17-sulfanyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 21002-48-2
• 化学式: C₁₉H₃₀OS
• 分子量: 306.513
• InChiKey: ARLFHPUIKLFDLD-LOVVWNRFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  17β-mercapto-androst-5-en-3β-ol 在 环己酮 、 aluminum isopropoxide 、 甲苯 作用下， 生成 S-(10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl) ethanethioate
  参考文献：
  名称：

  delta-17-thio-androsten-3-ones

  摘要：

  公开号：

  US02763669A1
• 作为产物：
  描述：

  3β-hydroxy-androst-5-ene-17-thione 在 甲醇 、 sodium tetrahydroborate 作用下， 生成 17β-mercapto-androst-5-en-3β-ol
  参考文献：
  名称：

  17-thio-5-androstene-3-ols

  摘要：

  公开号：

  US02753361A1

文献信息

• Treatment screening methods
  申请人：Frincke M. James

  公开号：US20060073099A1

  公开（公告）日：2006-04-06

  The invention includes a method to identify a method to enhance survival of a subject that has been exposed to a biological insult such as an ionizing radiation dose of LD 50/30 by treating the exposed subject with a test compound an optically comparing the results to that obtained using control subjects that had been treated with 3β,17β-dihydroxyandrost-5-ene or other disclosed compounds.

  本发明包括一种方法，用于确定如何提高受到生物损伤的受试者的存活率，如电离辐射剂量为 LD 50/30 用试验化合物处理受试者，并将结果与用 3β,17β-二羟基雄甾-5-烯或其他已公开化合物处理的对照受试者的结果进行光学比较。
• Steroidal sulfonium salts
  申请人：SEARLE &

  公开号：US02882281A1

  公开（公告）日：1959-04-14
• STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS
  申请人：Harbor BioSciences, Inc.

  公开号：EP1807118B1

  公开（公告）日：2014-03-12
• Steroid analogs and characterization and treatment methods
  申请人：Reading L. Christopher

  公开号：US20070014719A1

  公开（公告）日：2007-01-18

  The invention relates to methods to characterize exemplified compounds such as 3β, 17β-dihydroxyandrost-1,5,11 -triene and 3β, 17β-dihydroxy-17α-ethynylandrost-1,5,11-triene and to the use of described compounds to ameliorate or treat a condition such as thrombocytopenia, inflammation or other exemplified conditions.
• Drug product and process for making
  申请人：Frincke M. James

  公开号：US20070053832A1

  公开（公告）日：2007-03-08

  The invention provides a drug product for treating radiation exposure comprising, a drug in a dosage form; and packaging for the drug together with a package insert or label that includes information about the drug's efficacy, where the information about the drug's efficacy is obtained at least in part from methods described in the disclosure.